26 January 2026
26 January 2026
The two companies reportedly could not agree on a price, leaving pharma’s first potential megadeal of 2026 on ice.
NICE now recommends NHS use of the daily pill to patients with metastatic prostate cancer.
As more drugs go subcutaneous, Phillips Medisize's Tony Bedford believes that high-dose biologics will become a prevalent choice for drugmakers.
A spokesperson for the US Department of State told Pharmaceutical Technology that the “American people have paid more than enough” to the WHO.
This deal marks another addition to BMS’s growing pipeline, which the company hopes will stave off the impacts of the upcoming patent cliff.
Corxel’s lead candidate, CX11, is currently in a Phase II trial in the US and a Phase III trial in China.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
